Glow Nest Beauty sells unapproved injectable fat-dissolving drugs online, FDA warned.
What happened
In January 2025, FDA reviewed Glow Nest Beauty’s websites glownestbeauty.com and hyaworld.store and its Facebook and Instagram pages. FDA found injectable lipolytic products—PineBottle, Super V-Line Sol, LipoLab PPC Solution (brown bottle), and Deolipo—offered for sale in the U.S. with claims to remove fat, treat obesity, and affect skin. FDA concluded they are unapproved new drugs without approved applications.
What FDA found
The products are unapproved new drugs sold in interstate commerce without FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The websites and social media make drug claims that the injectable products remove fat, treat obesity, or affect body structure or function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA says the products are not generally recognized as safe and effective for their claimed uses, which makes them new drugs under the law.
FD&C Act section 201(p), 21 U.S.C. 321(p)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations, with explanations and supporting documents. If the company believes it is not in violation, it must include its reasoning and supporting information; if correction will take longer, it must state why and when it will be completed.
Who should pay attention
- online sellers of injectable cosmetic drugs
- med spas and clinics buying lipolytic injections
- consumers considering injectable fat-dissolving products
This is a summary. Read the original letter on fda.gov.